Biotech News

Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related Heart Failure Rivus Pharmaceuticals Logo (PRNewsfoto/Rivus Pharmaceuticals)

CHARLOTTESVILLE, Va. and SAN FRANCISCO, Sept. 30, 2024 /PRNewswire/ — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving metabolic health, today announced new clinical data from the Phase 2a HuMAIN study of...